DRKS00004744进行中（未招募）1 期
A phase I study of TKI258 and capecitabine in patients with advanced pancreatic cancer and treatment failure after first-line chemotherapy - CAPDOV
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •Male or female patients age 18-90, with histologically proven chemo-refractory pancreatic cancer patients must have recovered from side effects of previous chemotherapy. Life expectancy must be more than 12 weeks, organ functions must be adequate.
排除标准
- •The patients must not suffer from any other severe chronic or acute medical or psychiatric disorder. They must be at least 2 weeks from last chemotherapy and must not receive any other conventional medicinal anti-cancer therapy during the treatment phase.
研究者
相似试验
已完成
2 期
Phase II study of lapatinib plus capecitabin for the HER2 overexpressing metastatic breast cancer patients pretreated with oral-FU agents.Breast cancerJPRN-UMIN000002456Saitama Breast Cancer Clinical Study Group(SBCCSG)30
已完成
1 期
Capecitabine and erlotinib in advanced lung cancerCancerISRCTN18199864Royal Marsden NHS Foundation Trust40
已完成
不适用
A Phase I/II Study of Carboplatin and TS-1 in Patients with Advanced Non-small Cell Lung Cancer: CJLSG-0402Advanced non-small cell lung cancerJPRN-C000000234Central Japan Lung Study Group32
已完成
1 期
Phase I study of a combination of capecitabine plus CPT-11 (CC therapy) in patients with metastatic colon cancer refractory to oxaliplatin containing chemotherapyColorectal cancerJPRN-UMIN000003176Osaka Medical Center for Cancer and Cardiovascular Diseases24
进行中（未招募）
1 期
A Phase II study of lapatanib and capecitabine in the treatment of metastatic pancreatic cancer - metastatic pancreatic cancer trialMetastatic pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticEUCTR2008-006907-22-IEICORG - the All-Ireland Cooperative Oncology Research Group57